Abstract
Invasive nonfunctional pituitary adenomas (NFPAs) are difficult to completely resect and often develop tumor recurrence after initial surgery. Currently, no medications are clinically effective in the control of NFPA. Although radiation therapy and radiosurgery are useful to prevent tumor regrowth, they are frequently withheld because of severe complications. Boron neutron capture therapy (BNCT) is a binary radiotherapy that selectively and maximally damages tumor cells without harming the surrounding normal tissue. Folate receptor (FR)-targeted boron-10 containing carbon nanoparticles is a novel boron delivery agent that can be selectively taken up by FR-expressing cells via FR-mediated endocytosis. In this study, FR-targeted boron-10 containing carbon nanoparticles were selectively taken up by NFPAs cells expressing FR but not other types of non-FR expressing pituitary adenomas. After incubation with boron-10 containing carbon nanoparticles and following irradiation with thermal neutrons, the cell viability of NFPAs was significantly decreased, while apoptotic cells were simultaneously increased. However, cells administered the same dose of FR-targeted boron-10 containing carbon nanoparticles without neutron irradiation or received the same neutron irradiation alone did not show significant decrease in cell viability or increase in apoptotic cells. The expression of Bcl-2 was down-regulated and the expression of Bax was up-regulated in NFPAs after treatment with FR-mediated BNCT. In conclusion, FR-targeted boron-10 containing carbon nanoparticles may be an ideal delivery system of boron to NFPAs cells for BNCT. Furthermore, our study also provides a novel insight into therapeutic strategies for invasive NFPA refractory to conventional therapy, while exploring these new applications of BNCT for tumors, especially benign tumors.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Asa S L, Ezzat S. The pathogenesis of pituitary tumours. Nat Rev Cancer, 2002, 2: 836–849
Asa S L, Kovacs K. Clinically non-functioning human pituitary adenomas. Can J Neurol Sci, 1992, 19: 228–235
Chang E F, Zada G, Kim S, et al. Long-term recurrence and mortality after surgery and adjuvant radiotherapy for nonfunctional pituitary adenomas. J Neurosurg, 2008, 108: 736–745
Losa M, Picozzi P, Motta M, et al. The role of radiation therapy in the management of non-functioning pituitary adenomas. J Endocrinol Invest, 2011, 34: 623–629
Pollock B E, Cochran J, Natt N, et al. Gamma knife radiosurgery for patients with nonfunctioning pituitary adenomas: results from a 15-year experience. Int J Radiat Oncol Biol Phys, 2008, 70: 1325–1329
Feigl G C, Pistracher K, Berghold A, et al. Pituitary insufficiency as a side effect after radiosurgery for pituitary adenomas: the role of the hypothalamus. J Neurosurg, 2010, 113(Suppl): 153–159
Barth R F. Boron neutron capture therapy at the crossroads: challenges and opportunities. Appl Radiat Isot, 2009, 67: S3–S6
Pisarev M A, Dagrosa M A, Juvenal G J. Boron neutron capture therapy in cancer: past, present and future. Arq Bras Endocrinol Metabol, 2007, 51: 852–856
Barth R F, Coderre J A, Vicente M G, et al. Boron neutron capture therapy of cancer: current status and future prospects. Clin Cancer Res, 2005, 11: 3987–4002
Barth R F, Soloway A H, Fairchild R G, et al. Boron neutron capture therapy for cancer. Realities and prospects. Cancer, 1992, 70: 2995–3007
Barth R F, Yang W, Rotaru J H, et al. Boron neutron capture therapy of brain tumors: enhanced survival and cure following blood-brain barrier disruption and intracarotid injection of sodium borocaptate and boronophenylalanine. Int J Radiat Oncol Biol Phys, 2000, 47: 209–218
Panov V, Salomon Y, Kabalka G W, et al. Uptake and washout of borocaptate sodium and borono-phenylalanine in cultured melanoma cells: a multi-nuclear NMR study. Radiat Res, 2000, 154: 104–112
Sudimack J, Lee R J. Targeted drug delivery via the folate receptor. Adv Drug Deliv Rev, 2000, 41: 147–162
Hwang K C, Lai P D, Chiang C S, et al. Neutron capture nuclei-containing carbon nanoparticles for destruction of cancer cells. Biomaterials, 2010, 31: 8419–8425
Evans C O, Reddy P, Brat D J, et al. Differential expression of folate receptor in pituitary adenomas. Cancer Res, 2003, 63: 4218–4224
Liu X, Ma S, Yao Y, et al. Differential expression of folate receptor alpha in pituitary adenomas and its relationship to tumor behavior. Neurosurgery, 2012, 70: 1274–1280
Ke G, Sun Z, Shen F, et al. The study of physics and thermal characteristics for in-hospital neutron irradiator (IHNI). Appl Radiat Isot, 2009, 67: S234–S237
Linko S, Revitzer H, Zilliacus R, et al. Boron detection from blood samples by ICP-AES and ICP-MS during boron neutron capture therapy. Scand J Clin Lab Invest, 2008, 68: 696–702
Zhang L, Xing D, Chen M. Bim(L) displacing Bcl-x(L) promotes Bax translocation during TNFalpha-induced apoptosis. Apoptosis, 2008, 13: 950–958
Kawabata S, Miyatake S, Nonoguchi N, et al. Survival benefit from boron neutron capture therapy for the newly diagnosed glioblastoma patients. Appl Radiat Isot, 2009, 67: S15–S18
Santa C G, Gonzalez S J, Bertotti J, et al. First application of dynamic infrared imaging in boron neutron capture therapy for cutaneous malignant melanoma. Med Phys, 2009, 36: 4519–4529
Aihara T, Hiratsuka J, Morita N, et al. First clinical case of boron neutron capture therapy for head and neck malignancies using 18F-BPA PET. Head Neck, 2006, 28: 850–855
Kato I, Fujita Y, Maruhashi A, et al. Effectiveness of boron neutron capture therapy for recurrent head and neck malignancies. Appl Radiat Isot, 2009, 67: S37–S42
Suzuki M, Sakurai Y, Masunaga S, et al. Dosimetric study of boron neutron capture therapy with borocaptate sodium (BSH)/lipiodol emulsion (BSH/lipiodol-BNCT) for treatment of multiple liver tumors. Int J Radiat Oncol Biol Phys, 2004, 58: 892–896
Kimura Y, Ariyoshi Y, Shimahara M, et al. Boron neutron capture therapy for recurrent oral cancer and metastasis of cervical lymph node. Appl Radiat Isot, 2009, 67: S47–S49
Colao A, Grasso L F, Pivonello R, et al. Therapy of aggressive pituitary tumors. Expert Opin Pharmacother, 2011, 12: 1561–1570
Evans C O, Young A N, Brown M R, et al. Novel patterns of gene expression in pituitary adenomas identified by complementary deoxyribonucleic acid microarrays and quantitative reverse transcription-polymerase chain reaction. J Clin Endocrinol Metab, 2001, 86: 3097–3107
Thirumamagal B T, Zhao X B, Bandyopadhyaya A K, et al. Receptor-targeted liposomal delivery of boron-containing cholesterol mimics for boron neutron capture therapy (BNCT). Bioconjug Chem, 2006, 17: 1141–1150
Stephenson S M, Yang W, Stevens P J, et al. Folate receptor-targeted liposomes as possible delivery vehicles for boron neutron capture therapy. Anticancer Res, 2003, 23: 3341–3345
Shukla S, Wu G, Chatterjee M, et al. Synthesis and biological evaluation of folate receptor-targeted boronated PAMAM dendrimers as potential agents for neutron capture therapy. Bioconjug Chem, 2003, 14: 158–167
Sudimack J J, Adams D, Rotaru J, et al. Folate receptor-mediated liposomal delivery of a lipophilic boron agent to tumor cells in vitro for neutron capture therapy. Pharm Res, 2002, 19: 1502–1508
Wang P, Zhen H, Jiang X, et al. Boron neutron capture therapy induces apoptosis of glioma cells through Bcl-2/Bax. BMC Cancer, 2010, 10: 661
Yanagihara K, Nii M, Numoto M, et al. Radiation-induced apoptotic cell death in human gastric epithelial tumour cells; correlation between mitotic death and apoptosis. Int J Radiat Biol, 1995, 67: 677–685
Yang J, Liu X, Bhalla K, et al. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science, 1997, 275: 1129–1132
Mahajan N P, Linder K, Berry G, et al. Bcl-2 and Bax interactions in mitochondria probed with green fluorescent protein and fluorescence resonance energy transfer. Nat Biotechnol, 1998, 16: 547–552
Guo B, Zhai D, Cabezas E, et al. Humanin peptide suppresses apoptosis by interfering with Bax activation. Nature, 2003, 423: 456–461
Rosse T, Olivier R, Monney L, et al. Bcl-2 prolongs cell survival after Bax-induced release of cytochrome c. Nature, 1998, 391: 496–499
Author information
Authors and Affiliations
Corresponding author
Additional information
Contributed equally to this work
This article is published with open access at Springerlink.com
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 2.0 International License (https://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
About this article
Cite this article
Dai, C., Cai, F., Hwang, K.C. et al. Folate receptor-mediated boron-10 containing carbon nanoparticles as potential delivery vehicles for boron neutron capture therapy of nonfunctional pituitary adenomas. Sci. China Life Sci. 56, 163–173 (2013). https://doi.org/10.1007/s11427-012-4433-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11427-012-4433-5